Analyst picks & changes

Gensia Pharmaceuticals Inc.


Vector's Brown also reiterated a "buy," following the long-awaited announcement of GNSA's marketing collaboration on Geomatrix nifedipine (see Page B2). He has a 10-month price target of $35.

Brown also

Read the full 340 word article

How to gain access

Continue reading with a
two-week free trial.